Actively Recruiting
Evaluating THB335 for Adults with Chronic Spontaneous Urticaria Who Still Have Symptoms Despite Standard Treatment
Led by Calixis Inc. · Updated on 2026-11-02
81
Participants Needed
15
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of THB335 in adults with chronic spontaneous urticaria CSU who continue to experience hives and itching despite treatment with a second-generation H1 antihistamine. This Phase 2, randomized, double-blind, placebo-controlled study aims to compare two doses of THB335 against a placebo. The study is designed for adults aged 18 to 85 who remain symptomatic despite standard care. Participants will be randomly assigned to receive either a higher dose or a lower dose of THB335, or a matching placebo, taken orally once daily for 12 weeks. All participants will continue their stable antihistamine treatment during this period. The study includes a Screening Period of up to 4 weeks before treatment, followed by a 12-week Treatment Period, and then a 4-week Follow-Up Period. During the trial, participants will complete daily electronic diaries to track symptoms such as hives and itching, and attend scheduled study visits for assessments. Researchers will measure changes in weekly Urticaria Activity Score UAS7 and other related scores from baseline to Week 12. Safety will be monitored through the recording of adverse events, vital signs, and laboratory tests up to Week 16. Overall, the total participation time is approximately 20 weeks.
CONDITIONS
Brief Title
A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)
Research Team
C
Clinical Trials Monitor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here